The MNT aimed at EGFR, with epidermal growth factor (EGF) serving as a ligand module, is attractive for the clinic because EGFR expression is enhanced in many malignances, including lung cancer (Hirsch et al., 2003), head and neck cancer (Kalyankrishna and Grandis, 2006), bladder transitional cell carcinomas (Chow et al., 2001), etc. In this study, we evaluated the therapeutic potential and pharmacokinetics profile of the AE emitter 111In delivered by EGFR-targeted MNTs to human bladder tumor cells in vitro and in vivo. Here, EGF is linked to lung carcinoma.